Vaccine development and infectious disease research sit at one of the most demanding intersections in modern medicine. The assays that measure immune protection, viral clearance, and therapeutic response must be sensitive enough to detect the biology that matters, robust enough to perform consistently across sites, and rigorous enough to satisfy regulatory agencies worldwide. Purpose-built bioanalytical services are what make that standard achievable.
From early discovery through Phase 3 clinical trials, the measurement tools a program relies on shape every scientific and regulatory decision it makes.
The Complexity of Infectious Disease Bioanalysis
Infectious disease research demands assays that work across a wide range of pathogen types, sample matrices, and immune response mechanisms. Viral load quantification, neutralizing antibody detection, antigen-specific T-cell measurement, and reservoir quantification all require different technical approaches. Bringing these under one roof reduces complexity for sponsors and ensures methodological consistency across endpoints.
Supported pathogen areas include HIV, HBV, HDV, influenza, RSV, and emerging pathogens. Ultrasensitive viral load assays and reservoir quantification methods push detection limits well below those achievable with standard platforms. Viral persistence models and neutralization assays round out a comprehensive infectious disease bioanalytical portfolio.
HIV Reservoir Research and Ultrasensitive Detection
HIV cure research is particularly demanding from a bioanalytical perspective. Reservoir studies require detecting rare infected cells or integrated proviral DNA at extremely low frequencies in complex biological samples. Standard qPCR platforms often lack the sensitivity needed for this work. Digital PCR platforms that achieve limits of detection well below 50 copies per mL represent a meaningful technical advance for this application.
PBMCs from HIV-positive donors require infectious sample handling under BSL-2+ conditions, a capability that many reference laboratories are not equipped to offer. Specialized processing for infectious samples, combined with ultrasensitive molecular quantification, enables the kind of research that drives HIV reservoir science forward.
Vaccine Immunogenicity Monitoring
Vaccine efficacy ultimately comes down to the immune response the vaccine generates. Measuring that response accurately and reproducibly is the central challenge of vaccine bioanalysis. Immunogenicity endpoints include antibody titers, neutralizing antibody levels, antigen-specific T-cell frequencies, cytokine profiles, and memory B-cell responses.
PBMC processing services are fundamental to several of these endpoints. ELISpot assays measuring antigen-specific T-cell frequencies depend entirely on cell viability and functional integrity. Flow cytometry-based phenotyping of memory subsets requires that cryopreservation did not compromise the surface markers being measured. Getting the upstream processing right is what makes vaccine immunogenicity data credible.
Longitudinal Immune Monitoring for Vaccine Trials
Vaccine trials often require longitudinal collection and analysis. Subjects are sampled at multiple time points before and after vaccination, and the data from these time points must be directly comparable. This requires consistent collection procedures, standardized processing protocols, and rigorous QC at every step.
Key capabilities for longitudinal vaccine bioanalysis include:
- Cryopreserved PBMC banking with donor-matched lot availability
- Standardized ELISpot protocols with validated positive and negative controls
- Multiplex cytokine profiling for comprehensive immune response characterization
- Neutralization assay development and validation for vaccine candidates
- Longitudinal tracking of antibody isotypes and avidity maturation
Regulatory Readiness for Vaccine and Infectious Disease Programs
Regulatory submissions for vaccines and infectious disease products carry their own specific requirements. The FDA and EMA both expect assay validation data that demonstrates performance across the full range of anticipated sample conditions, including challenging matrices, low-abundance targets, and multi-site collection scenarios.
Operating under a CLIA-certified quality management system with GLP-compatible workflows means every method is built to withstand regulatory scrutiny. Documented validation of precision, specificity, linearity, robustness, and sensitivity provides the foundation for a defensible data package.
Supporting IND and BLA Submissions
From IND-enabling studies through BLA preparation, bioanalytical data threads through the entire regulatory narrative. Companion diagnostic assay support and fit-for-purpose biomarker development add further depth to the regulatory package for vaccine and infectious disease programs.
Accelevir's team engages at the study design stage to ensure the bioanalytical strategy is aligned with the regulatory pathway. This front-end investment in strategy avoids the expensive assay rework that comes from discovering gaps late in development.
Conclusion
Vaccine and infectious disease programs need bioanalytical services that match the scientific and regulatory complexity of what they are trying to measure. From ultrasensitive viral reservoir quantification to validated vaccine immunogenicity assays, the right laboratory partner brings both the scientific depth and the regulatory fluency to make your program's data count when it matters most.